Philip Dean, CSO at De Novo, said: “We are very pleased to be working with Achaogen – a leader in the fight against drug-resistant bacteria.”
Phillip Patten, senior vice president, added: “We are pleased to be working with De Novo to expand our lead optimization program, and to help us develop cutting-edge therapeutics that will speed us towards our goal of providing therapies to treat unmet clinical needs caused by multi-drug resistant bacterial infections.”
Financial terms of the agreement were not disclosed.